Monopar Therapeutics (MNPR) Retained Earnings (2016 - 2020)

Monopar Therapeutics' Retained Earnings history spans 5 years, with the latest figure at -$10044.0 for Q3 2020.

  • For Q3 2020, Retained Earnings rose 17.64% year-over-year to -$10044.0; the TTM value through Sep 2020 reached -$10044.0, up 17.64%, while the annual FY2019 figure was -$10970.0, 99.95% up from the prior year.
  • Retained Earnings for Q3 2020 was -$10044.0 at Monopar Therapeutics, up from -$28.4 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$1579.0 in Q2 2018 and bottomed at -$28.4 million in Q2 2020.
  • The 5-year median for Retained Earnings is -$1.9 million (2016), against an average of -$10.7 million.
  • The largest annual shift saw Retained Earnings skyrocketed 99.95% in 2019 before it tumbled 822159.06% in 2020.
  • A 5-year view of Retained Earnings shows it stood at -$1.9 million in 2016, then tumbled by 883.91% to -$18.4 million in 2017, then dropped by 17.52% to -$21.7 million in 2018, then surged by 99.95% to -$10970.0 in 2019, then grew by 8.44% to -$10044.0 in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Retained Earnings are -$10044.0 (Q3 2020), -$28.4 million (Q2 2020), and -$27.0 million (Q1 2020).